3 Drugs Stocks On The Rise

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 95 points (0.6%) at 16,678 as of Monday, May 12, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,394 issues advancing vs. 601 declining with 132 unchanged.

The Drugs industry currently sits up 1.7% versus the S&P 500, which is up 0.8%. Top gainers within the industry include Regeneron Pharmaceuticals ( REGN), up 3.9%, Alexion Pharmaceuticals ( ALXN), up 3.4%, Vertex Pharmaceuticals ( VRTX), up 2.6%, Grifols ( GRFS), up 2.4% and Mylan ( MYL), up 2.4%. A company within the industry that fell today was Shire ( SHPG), up 0.8%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Bristol-Myers Squibb Company ( BMY) is one of the companies pushing the Drugs industry higher today. As of noon trading, Bristol-Myers Squibb Company is up $0.88 (1.7%) to $52.06 on average volume. Thus far, 4.7 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 8.5 million shares. The stock has ranged in price between $51.35-$52.31 after having opened the day at $51.52 as compared to the previous trading day's close of $51.18.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company has a market cap of $84.1 billion and is part of the health care sector. Shares are down 3.7% year-to-date as of the close of trading on Friday. Currently there are 11 analysts who rate Bristol-Myers Squibb Company a buy, 2 analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, good cash flow from operations, solid stock price performance and notable return on equity. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Bristol-Myers Squibb Company Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Biogen Idec ( BIIB) is up $11.00 (3.8%) to $297.65 on average volume. Thus far, 842,119 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $288.01-$299.10 after having opened the day at $289.78 as compared to the previous trading day's close of $286.65.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of multiple sclerosis (MS), neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $67.1 billion and is part of the health care sector. Shares are up 2.5% year-to-date as of the close of trading on Friday. Currently there are 13 analysts who rate Biogen Idec a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Biogen Idec Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Actavis ( ACT) is up $6.45 (3.3%) to $202.63 on average volume. Thus far, 1.2 million shares of Actavis exchanged hands as compared to its average daily volume of 3.0 million shares. The stock has ranged in price between $197.28-$203.44 after having opened the day at $199.97 as compared to the previous trading day's close of $196.18.

Actavis plc, an integrated specialty pharmaceutical company, is engaged in the development, manufacture, marketing, sale, and distribution of pharmaceutical products in the Americas, Europe, the Middle East, Africa, Australia, and the Asia Pacific. Actavis has a market cap of $34.4 billion and is part of the health care sector. Shares are up 16.8% year-to-date as of the close of trading on Friday. Currently there are 14 analysts who rate Actavis a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Actavis as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and generally higher debt management risk. Get the full Actavis Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists